Clinical Diagnosis of COVID-19: A Prompt, Feasible, and Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis)

Three years ago, a study was conducted on 1,757 patients to propose a clinical scoring system for the diagnosis of COVID-19, known as the AndroCoV Clinical Scoring for COVID-19 Diagnosis. The study aimed to address the challenges of early diagnosis due to unspecific and mild symptoms, cost and time limitations of the rtPCR-SARS-CoV-2 test, and its insufficient sensitivity for screening during the pandemic. The scoring system was based on the likelihood of having COVID-19 according to the number of symptoms, presence of anosmia, and known positive household contact. The study found that requiring two or more symptoms with or without anosmia or ageusia for subjects without known contact and one or more symptoms with or without anosmia or ageusia with known positive contacts presented the highest accuracy (80.4%). The AndroCoV Clinical Scoring for COVID-19 Diagnosis was found to be a feasible, quick, inexpensive, and sensitive diagnostic tool for clinical diagnosis of COVID-19, and was recommended as a first-line option for COVID-19 diagnosis for public health policies.